X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Chemomab expects to use net proceeds from this private placement to advance in parallel three Phase 2 clinical trials for its lead product, CM-101, a novel antibody for treating rare fibrotic conditions, as well as to further develop its earlier-stage pipeline.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ChemomAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 16, 2021
Details:
Financing will be used to advance the Chemomab pipeline. Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cormorant Asset Management
Deal Size: $45.5 million Upfront Cash: Undisclosed
Deal Type: Financing March 15, 2021
Details:
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ChemomAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
